|
I. MODIFIED AGREEMENTS | |||
Company* (Country; Symbol) | Company* (Country; Symbol) | Change from original agreement | Terms/Details (Date) |
| | |||
Corixa Corp. (CRXA) and GlaxoSmithKline plc (UK) |
Biogen Idec Inc. (BIIB) |
Companies settled all litigation related to patents on cancer radioimmunotherapy |
Biogen is paying Corixa and GSK $20M up front, a milestone payment related to future Zevalin sales, and royalties on Zevalin sales until Bexxar patents expire in 2013 (3/1) |
Crucell NV (the Netherlands; CRXL) |
ML Laboratories plc (UK; LSE:MLB) |
ML renewed its license to use Crucell's PER.C6 technology |
The companies negotiated research and commercial terms covering gene therapy products; details were not disclosed (3/16) |
Pharmacopeia Inc. (ACCL) |
Celgene Corp. (CELG) |
Extended and expanded deal under which Pharmacopeia will identify leads against selected Celgene targets |
Pharmacopeia will receive research funding and could earn milestone and royalty payments (3/23) |
SurroMed Inc.* |
Biogen Idec Inc. (BIIB) |
Extension to June 2002 deal to characterize responses to Biogen's Avonex in patients with multiple sclerosis |
SurroMed is analyzing patient samples in its Biomarker Discovery Laboratory; terms were not disclosed (3/11) |
Transgenomic Inc. (TBIO) |
Geron Corp. (GERN) |
Amended deal under which Transgenomic will provide additional compounds to Geron |
The modified nucleic acid building block compounds will be used in the synthesis of Geron's cancer drug GRN163L; terms were not disclosed (4/28) |
II. TERMINATED AGREEMENTS | |||
Immunomedics Inc. (IMMU) |
Amgen Inc. (AMGN) |
Amgen returned all rights to epratuzumab, a humanized CD22 monoclonal antibody licensed in December 2000 |
Amgen will get a five-year warrant to pur- chase 100,000 Immunomedics shares at $16 per share, and would get $600,000 if the drug is approved in the U.S.; those terms satsify all financial obligations (4/8) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange. | |||
